Liaoning Cancer Hospital & Institute | China
Publication Profile
🔬 Dr. Yu Zeng: Advancing Urologic Oncology Through Precision Research & Clinical Excellence 🏥🧠
🧑🎓 Education & Experience
Dr. Yu Zeng holds a PhD jointly from China Medical University and Kagawa University. He completed postdoctoral training at Johns Hopkins University, gaining significant exposure to cutting-edge research in urologic oncology. Currently serving as a surgeon at Liaoning Cancer Hospital & Institute, Dr. Zeng has a robust blend of clinical expertise and translational research experience in urological cancers.
✅ Suitability Summary
With over 15 peer-reviewed SCI publications, an H-index of 9, and a focus on cancer stem cells and metabolic reprogramming in urologic oncology, Dr. Zeng is a well-qualified expert in his field. His background in international research environments and clinical trial participation positions him as a key contributor to advancements in prostate and bladder cancer therapeutics.
🌍📜 Professional Development
-
Postdoctoral Fellow, Johns Hopkins University
-
PhD, China Medical University & Kagawa University
-
Committee Member, Liaoning Medical Association Urology Branch
-
Editor, World Journal of Urology
-
Co-author, Wu Jieping Urology (ISBN 978-7-117-28274-1)
-
Clinical Trial Consultant in Urology
-
Collaborator with Dr. Dong Gao, Chinese Academy of Sciences
🔬🧠 Research Focus
Dr. Zeng’s research spans prostate cancer stem cells, RNA-based therapies, and cancer metabolism. Notably, he has explored the inhibitory effects of mannose on bladder cancer, contributing to the understanding of sugar metabolism in tumor growth. His collaborative efforts in molecular cell science further strengthen his translational impact on therapeutic strategies in urologic oncology.
🏆🎖️ Honors & Awards
-
Editorial appointment at World Journal of Urology
-
Recognition for collaborative research with leading Chinese institutions
-
Contributor to high-impact clinical trials and peer-reviewed publications
📚 Top Notes Publications
Article: Epigenetic Modifications in Prostate Cancer Metastasis and Microenvironment
Article: Gypenoside‐Induced Apoptosis via the PI3K/AKT/mTOR Signaling Pathway in Bladder Cancer
-
Authors: Xiuming Li, Hui Liu, Chengcheng Lv, Jun Du, Fangchao Lian, Shouyi Zhang, Zhiyong Wang, Yu Zeng, Shi Yong Sun
-
Journal: BioMed Research International
-
Year: 2022
-
DOI: 10.1155/2022/9304552